General Information of Drug Combination (ID: DCWQ8GD)

Drug Combination Name
RTB101 Ridaforolimus
Indication
Disease Entry Status REF
Adenocarcinoma Investigative [1]
Component Drugs RTB101   DM62QTW Ridaforolimus   DMLHEU7
Small molecular drug Small molecular drug
High-throughput Screening Result Testing Cell Line: OVCAR3
Zero Interaction Potency (ZIP) Score: 2.76
Bliss Independence Score: 2.86
Loewe Additivity Score: 2.83
LHighest Single Agent (HSA) Score: 7.23

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of RTB101
Disease Entry ICD 11 Status REF
Respiratory tract infection CA45 Phase 3 [2]
Coronavirus Disease 2019 (COVID-19) 1D6Y Phase 2 [3]
RTB101 Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
CREB-regulated transcription coactivator 1 (TORC1) TT4GO0F CRTC1_HUMAN Inhibitor [5]
------------------------------------------------------------------------------------
Indication(s) of Ridaforolimus
Disease Entry ICD 11 Status REF
Sarcoma 2A60-2C35 Phase 3 [4]
Ridaforolimus Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
Serine/threonine-protein kinase mTOR (mTOR) TTCJG29 MTOR_HUMAN Inhibitor [6]
------------------------------------------------------------------------------------

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Ewing sarcoma-peripheral primitive neuroectodermal tumour DCG1N85 ES2 Investigative [7]
Breast and ovarian cancer syndrome DCDS03D UWB1289 Investigative [8]
Breast and ovarian cancer syndrome DCXFJ3A UWB1289+BRCA1 Investigative [8]
Breast carcinoma DCLQE0M KPL1 Investigative [8]
Breast carcinoma DCL12U8 OCUBM Investigative [8]
Carcinoma DCVCHPB OV90 Investigative [8]
Carcinoma DC42M44 EFM192B Investigative [8]
Carcinoma DCSMB49 MDAMB436 Investigative [8]
Colon adenocarcinoma DC32D75 LOVO Investigative [8]
Colon carcinoma DCON33B RKO Investigative [8]
Invasive ductal carcinoma DCQBGAY T-47D Investigative [8]
Rectal adenocarcinoma DCB3AZD SW837 Investigative [8]
Adenocarcinoma DCDAC43 CAOV3 Investigative [1]
Adenocarcinoma DCNN60Y A427 Investigative [1]
Adenocarcinoma DC633J4 NCIH1650 Investigative [1]
Adenocarcinoma DCK1RN6 NCIH2122 Investigative [1]
Adenocarcinoma DC11JDJ NCIH23 Investigative [1]
Adenocarcinoma DC2FP5T NCIH520 Investigative [1]
Adenocarcinoma DCAAG7Z COLO320DM Investigative [1]
Adenocarcinoma DCYA1NH DLD1 Investigative [1]
Adenocarcinoma DC1JPKC HT29 Investigative [1]
Adenocarcinoma DCI3XU5 SW-620 Investigative [1]
Amelanotic melanoma DCVFEF2 A2058 Investigative [1]
Germ cell tumour DC6B4WV PA1 Investigative [1]
Large cell lung carcinoma DCVYWZH NCI-H460 Investigative [1]
Malignant melanoma DCP24AP A375 Investigative [1]
Malignant melanoma DCWP25P HT144 Investigative [1]
Malignant melanoma DC7KTTZ RPMI7951 Investigative [1]
Malignant melanoma DCJH8R6 SKMEL30 Investigative [1]
Malignant melanoma DCGTM6F UACC62 Investigative [1]
Mesothelioma DCPKBCI MSTO Investigative [1]
Non small cell carcinoma DCH0RMP SKMES1 Investigative [1]
Ovarian endometrioid adenocarcinoma DC6P8BI A2780 Investigative [1]
Ovarian serous cystadenocarcinoma DCUA4QR SK-OV-3 Investigative [1]
Prostate carcinoma DC1AMWS VCAP Investigative [1]
Prostate carcinoma DCD3KOO LNCAP Investigative [1]
------------------------------------------------------------------------------------
⏷ Show the Full List of 36 DrugCom(s)

References

1 Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.
2 ClinicalTrials.gov (NCT04139915) Effect of RTB101 on Illness Associated With Respiratory Tract Infections in the Elderly. U.S. National Institutes of Health.
3 ClinicalTrials.gov (NCT04409327) Phase 2 Study to Determine if RTB101 Reduces the Severity of COVID-19 in Older Adults Residing in Nursing Homes. U.S. National Institutes of Health.
4 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7884).
5 Anti-ageing pipeline starts to mature.Nat Rev Drug Discov. 2018 Sep;17(9):609-612.
6 A novel c-Met inhibitor, MK8033, synergizes with carboplatin plus paclitaxel to inhibit ovarian cancer cell growth. Oncol Rep. 2013 May;29(5):2011-8.
7 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
8 Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.